Pembrolizumab
E7080-G000-309
Phase 3 small_molecule completed
Quick answer
Pembrolizumab for Endometrial Neoplasms is a Phase 3 program (small_molecule) at Eisai Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai Co.,
- Indication
- Endometrial Neoplasms
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed